Prepare for your visit

Robert M Tuttle

Endocrinology, Diabetes & Metabolism · New York, NY · NPI 1356312854

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$23,416.25

in general payments reported to CMS, 2019-2025 · $249 in 2025

The $249 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Who reported paying

General payments only, top 6 by amount.

Sanofi-Aventis U.S. LLC $9,619.55
Eisai Co., LTD. $5,175.00
Roche Diagnostics Operations, INC. $4,607.76
Glaxosmithkline, LLC. $2,700.00
Astrazeneca Pharmaceuticals LP $700.00
Novo Nordisk As $138.04

Drugs and devices associated with these payments

Nubeqa Libtayo

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Robert Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/242526/robert-m-tuttle